Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07452406 · ClinicalTrials.gov registry record · NA
Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients
A NA study, sponsored by Rush University Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 2,000
- Enrollment target
NCT07452406: Clinical Trial NA study, sponsored by Rush University Medical Center.
NCT07452406 is a NA study that has not yet begun recruiting, run by Rush University Medical Center. The registered enrollment target is 2,000 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07452406, a NA study, has not yet begun recruiting, sponsored by Rush University Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
High-flow nasal cannula (HFNC) is a type of oxygen therapy commonly used in adults with breathing problems. While HFNC can help patients avoid breathing tubes and improve oxygen levels, there is no standard method for deciding how and when to reduce and stop this therapy once a patient improves. In many hospitals, these decisions vary from clinician to clinician. This study will compare usual care with a standardized step-by-step plan for reducing HFNC support. Eight hospitals will participate and will switch from usual care to the standardized plan at different time points during the study. The main goal is to determine whether the standardized weaning plan increases the number of patients who can successfully stop HFNC within 5 days. The study will also evaluate how long patients remain on HFNC, whether they need additional breathing support, and how long they stay in the hospital. The results may help develop clearer guidance for safely and efficiently stopping HFNC therapy.
Primary Outcome
HFNC weaning success is defined as discontinuation of high-flow nasal cannula therapy with the participant alive and breathing on conventional oxygen therapy or room air without need for noninvasive ventilation, CPAP, invasive mechanical ventilation, or re-initiation of HFNC within 24 hours of discontinuation. Participants remaining on HFNC beyond Day 5 are considered weaning failures.
Interventions
- BEHAVIORAL Protocolized HFNC Weaning Strategy
- BEHAVIORAL Usual Care HFNC Weaning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-06-28 |
| Phase | NA |
What is known before NCT07452406 opens enrollment
NCT07452406 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 2 interventions - of which Protocolized HFNC Weaning Strategy is the first listed.
NCT07452406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07452406 about?
NCT07452406 is a clinical study titled "Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients". High-flow nasal cannula (HFNC) is a type of oxygen therapy commonly used in adults with breathing problems. While HFNC can help patients avoid breathing tubes and improve oxygen levels, there is no standard method for deciding how and when to reduce and stop this therapy once a patient improves. In ...
What is the current status of trial NCT07452406?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2026-09-01. Estimated completion is 2028-06-28.
What interventions are being tested in trial NCT07452406?
The interventions under investigation include: Protocolized HFNC Weaning Strategy (BEHAVIORAL), Usual Care HFNC Weaning (BEHAVIORAL).
Who is sponsoring clinical trial NCT07452406?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07452406's enrollment target sits among peer trials
2,000 52nd of 2000 higher than 1,947 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI